Top Back to top

A prospective study on the use of Brentuximab Vedotin or Checkpoint inhibitors as bridge to autologous stem cell transplantation in Hodgkin lymphoma

Lymphoma Working Party (LWP)
Study number:
2021-N-02
Diseases:
 
Short title:
 
Study status:
 
Deadline for data collection:
 
Study design:
 
Primary objective:
 
Key inclusion criteria:
 
Country:
 
Principal investigator:
Ali Bazarbachi
Principal investigator email:
bazarbac@aub.edu.lb
EBMT Study coordinator:
Irma Khvedelidze
Study coordinator email:
irma.khvedelidze@upmc.fr